The Global Peanut Allergy Vaccines Market: The key driving factor is high presence of infectious diseases, increase in industry’s initiatives to enhance vaccine research and development, and the rising focus on immunization.

Published Date: 16/05/2021

The Global Peanut Allergy Vaccines Market is currently valued at $2800 Million in 2020. At a CAGR of 111% it is projected to reach $4.5 billion by 2027.For a severe allergic reaction, you may need an emergency injection of epinephrine and to visit the emergency room. Many people with allergies carry an epinephrine autoinjector (EpiPen, Auvi-Q). For a mild reaction, to reduce your symptoms you may only need to take an antihistamine, such as a no drowsy one like loratadine (Claritin) or some sleep driving medicine like diphenhydramine (Benadryl). Thus, as more people generally have mild reactions only so the Antihistamines are more in use than the Epinephrine injection.

By Route of Administration: Oral, Injectable

For a mild reaction of the peanut allergy, the patient is advised to take the medication for which the route of administration is oral whereas for the severe infections, Epinephrine injectors are preferred. Thus, the oral route of administration is more in use because of the less severe cases among the patients.

By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Store

In terms of the Distribution Channel, the Market for the peanut allergy vaccine is dominated by the Hospital pharmacies because it can’t be known until you meet the doctor in the hospitals, followed by retail pharmacies and drug stores because over the counter (OTC) medicines is one that the U.S. Food and Drug Administration (FDA) has found to be safe and effective for direct consumer use based on the label instructions and warnings.

Regional Analysis:
Studies says that North America holds a Major Share of Global Peanut Allergy Treatment Market. North America is likely to dominate the global peanut allergy treatment market, followed by Europe and Asia Pacific. This dominance is mainly due to the US having a large population of potential patient Peanut allergy treatment market in Europe and Asia Pacific is also anticipated to witness substantial growth during the forecast period due to rise in the number of food related allergy testing and per capita health care spending by the regions. Peanuts are one of the most common food allergies and is the most likely food to cause anaphylaxis or death. In Australia, there is particularly high presence of peanut allergies with one in 200 adults, and almost three in every 100 children affected. It is more common in people with lower income (1.7% vs. 1.2%), males (1.7% vs. 0.8%), and there are race/ethnicity disparities in the prevalence of peanut allergies (1.7% Hispanics, 2.8% non-Hispanic blacks and 0.9% non-Hispanic whites)

Though the COVID-19 is the most trending disease in the world right now, still there are some allergies which are prevalent in the world. Many scientists all around the globe have been working on finding the vaccine for the COVID-19, many companies have been working on to develop vaccines for the peanut allergy also which has seen a tremendous growth in the past few years, with different regions improving on their per capita health care spending. Peanut allergy is an allergic reaction to peanuts, which is the leading cause of anaphylaxis, the most severe and potentially life-threatening allergic reaction, and the major reason for the death from food allergy in the US and other Western nations. It isn’t really why some people develop this sort of an allergy, but some of the major risk factors for this allergy are:
Age(children), Past allergy to peanuts, Family members with allergies, Atopic dermatitis, Other allergies.

It is estimated that peanut allergy vaccine market will grow at a CAGR of 111%, from sales worth of $2.6M in 2017, to reach sales level of $4.5B in 2027 with US being the leader of the market as US is the worst affected country by this allergy. The peanut allergy in Western countries ranges from 1.4-3% of children, with UK estimates around 2% of children for the peanut allergy in the country.